

# Assessment of A new Strategy to Prevent Prescribing Errors Involving COVID-19 Patients in Community Pharmacies

## Article Information

Article [first published online](#): April 4, 2022

[Derar H. Abdel-Qader](#)<sup>1</sup>, [Ahmad Z. Al Meslamani](#)<sup>2</sup>, [Abdullah Albassam](#)<sup>3</sup>, [Nadia Al Mazrouei](#)<sup>4</sup>, [Asma A. El-Shara](#)<sup>5</sup>, [Husam El Sharu](#)<sup>6</sup>, [Samah Bahy Mohammed Ebaed](#)<sup>7</sup>, [Osama Mohamed Ibrahim](#)<sup>4, 8</sup>

<sup>1</sup>University of Petra, Amman, Jordan

<sup>2</sup>AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United Arab Emirates

<sup>3</sup>Kuwait University, Kuwait

<sup>4</sup>University of Sharjah, Sharjah, United Arab Emirates

<sup>5</sup>Philadelphia University, Amman, Jordan

<sup>6</sup>Indiana University Center for Health Innovation and Implementation Science, Indianapolis, IN, USA

<sup>7</sup>Benha University, Benha, Egypt

<sup>8</sup>Cairo University, Cairo, Egypt

Corresponding Author:

Ahmad Z. Al Meslamani, AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United Arab Emirates. Emails: [amaslamani1095@gmail.com](mailto:amaslamani1095@gmail.com); [ahmad.almeslamani@aau.ac.ae](mailto:ahmad.almeslamani@aau.ac.ae)

## Abstract

**Background:** Because COVID-19 patients are vulnerable to prescribing errors (PEs) and adverse drug events, designing and implementing a new approach to prevent prescribing errors (PEs) involving COVID-19 patients has become a priority in pharmacotherapy research. **Objectives:** To investigate whether using WhatsApp to deliver prescribing error (PE)-related clinical scenarios to community pharmacists could enhance their ability to detect PEs and conduct successful pharmaceutical interventions (PIs). **Methods:** In this

study, 110 community pharmacies were recruited from different regions across Jordan and equally allocated to 2 groups. Over the course of 4 weeks, WhatsApp was used to send PEs-related clinical case scenarios to the active group. The second group was controlled with no clinical scenarios. After completion of the 4-week phase, pharmacists from both groups were asked to document PEs in COVID-19 patients and their interventions using a data-collection form. **Results:** The incidence of PEs in COVID-19 patients documented in the active group (18.54%) was higher than that reported in the control group (3.09%) ( $P = .001$ ). Of the 6598 and 968 PIs conducted by participants working in the active and control group pharmacies, 6013 (91.13%) and 651 (67.25%) were accepted, respectively. The proportions of wrong drug (contraindication), wrong drug (unnecessary drug prescribed/no proof of its benefits), and omission of a drug between the active and control groups were 15.30% versus 7.21% ( $P = .001$ ), 11.85% versus 6.29% ( $P = .03$ ), and 17.78% versus 10.50% (0.01), respectively. Additionally, the proportions of lethal, serious, and significant errors were 0.74% versus 0.35% ( $P = .04$ ), 10.52% versus 2.57% (0.002), and 47.88% versus 9.57% (0.001), respectively. Addition of drug therapy interventions (AOR = 0.62; 95% CI, 0.21-0.84) and errors with significant clinical seriousness (AOR = 0.32; 95% CI, 0.16-0.64). Conclusions PEs involving COVID-19 patients in community settings are common and clinically significant. The intervention assessed in this study could be promising for designing a feasible and time-efficient interventional tool to encourage pharmacists' involvement in identifying and correcting PEs in light of COVID-19.